Insider Selling: Heartflow (NASDAQ:HTFL) Major Shareholder Sells 254,110 Shares of Stock

Heartflow, Inc. (NASDAQ:HTFL) major shareholder Bain Capital Life Sciences Inv sold 254,110 shares of Heartflow stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $30.51, for a total value of $7,752,896.10. Following the sale, the insider directly owned 10,194,048 shares of the company’s stock, valued at approximately $311,020,404.48. This trade represents a 2.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Bain Capital Life Sciences Inv also recently made the following trade(s):

• On Thursday, April 30th, Bain Capital Life Sciences Inv sold 948,757 shares of Heartflow stock. The shares were sold at an average price of $29.23, for a total value of $27,732,167.11.
• On Wednesday, April 29th, Bain Capital Life Sciences Inv sold 797,133 shares of Heartflow stock. The shares were sold at an average price of $29.37, for a total value of $23,411,796.21.
• On Wednesday, February 4th, Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock. The shares were sold at an average price of $28.05, for a total value of $56,100,000.00.

Heartflow Stock Performance

NASDAQ:HTFL traded up $0.23 on Thursday, reaching $29.76. The company’s stock had a trading volume of 1,494,251 shares, compared to its average volume of 1,071,590. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $41.22. The firm has a market cap of $2.55 billion and a PE ratio of -14.95. The business’s 50-day moving average price is $26.11 and its two-hundred day moving average price is $29.28.

Analysts Set New Price Targets

A number of research analysts have issued reports on HTFL shares. Wells Fargo & Company decreased their target price on Heartflow from $38.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th. JPMorgan Chase & Co. decreased their target price on Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th. Finally, Canaccord Genuity Group boosted their target price on Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, March 19th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $37.67.

Institutional Trading of Heartflow

A number of institutional investors have recently modified their holdings of the company. Wellington Management Group LLP lifted its holdings in shares of Heartflow by 20.8% in the fourth quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock valued at $171,812,000 after purchasing an additional 1,014,006 shares in the last quarter. Baillie Gifford & Co. bought a new stake in shares of Heartflow in the third quarter valued at about $101,182,000. Bamco Inc. NY lifted its holdings in shares of Heartflow by 86.2% in the fourth quarter. Bamco Inc. NY now owns 2,303,877 shares of the company’s stock valued at $67,158,000 after purchasing an additional 1,066,371 shares in the last quarter. Schusterman Interests LLC bought a new stake in shares of Heartflow in the third quarter valued at about $65,274,000. Finally, Capricorn Investment Group LLC bought a new stake in shares of Heartflow in the fourth quarter valued at about $48,178,000.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.